Selvigaltin (GB1211), an orally available small molecule galectin-3 inhibitor formulated like a procedure for liver fibrosis and cirrhosis, was evaluated to assess the result of hepatic impairment on its pharmacokinetics and protection to address regulatory demands. Inhibition of galectin-three with GB1211 was not relevant to any procedure- or dose-associated trends https://stevek655ufp7.shoutmyblog.com/profile